An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects

Trial Profile

An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Jul 2015 Results published in the Advances in Therapy.
    • 15 Nov 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 27 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top